Oh cheer up . UNCY's trial ended with a whimper not a bang ( enrolled 106 but only had 71 to evaluate ....raised some questions as to market place viability ) . So OLC as a competitor now in doubt. Legislation was passed by the house , on its way to the Senate that will keep Xphazoh out of the dialysis bundle ( thats a good thing ) . ARDX is aggressively marketing X on websites visited by Nephrologists so even if the Medicare / Medicaid dialysis patients can't use the coupon ...at least about 20 % of dialysis patients that aren't on a Govt plan, can .
News 
Market Data 
Discover 
